最大摄氧量与男性非酒精性脂肪性肝病患者肝脏脂肪含量相关

肝脏 ›› 2023, Vol. 28 ›› Issue (3): 355-359.

最大摄氧量与男性非酒精性脂肪性肝病患者肝脏脂肪含量相关

刘晓慧, 勾钰淞, 梁珊, 任弘, 李强, 段威, 张晶

100069 首都医科大学附属北京佑安医院脂肪性肝病诊疗中心(刘晓慧,勾钰淞,梁珊,张晶);北京体育大学(任弘);北京市体检中心(李强);北京跑跑美美科技有限公司(段威)

收稿日期:2022-04-22 出版日期:2023-03-31 发布日期:2023-08-28
通讯作者: 张晶, Email: zjyouan@ccmu.edu.cn
基金资助:
首都医科大学附属北京佑安医院中青年人才孵育项目(YNKTQN2021015)

VO₂ max is correlated with liver steatosis in male nonalcoholic fatty liver patients

LIU Xiao-hui¹, GOU Yu-song¹, LIANG Shan¹, REN Hong², LI Qiang³, DUAN Wei⁴, ZHANG Jing¹

1. Fatty Liver Disease Treatment Center, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China;
2. Beijing Sport University, Beijing 100084, China;
3. Beijing Physical Examination Center, Beijing 100036, China;
4. Beijing Paopao-meimei Technology Co., Ltd, Beijing 100144, China

Received:2022-04-22 Online:2023-03-31 Published:2023-08-28
Contact: ZHANG Jing, Email: zjyouan@ccmu.edu.cn

摘要/Abstract

摘要： 目的探讨非酒精性脂肪性肝病(NAFLD)患者心肺适能水平与肝脏脂肪含量、炎症和肝纤维化的关系。方法入组62例NAFLD患者。采用最大摄氧量(maximal oxygen uptake,VO₂ max)来反映心肺适能,以受控衰减参数(controlled attenuated parameter, CAP)反映肝脏脂肪含量,同时检测生化学与人体成分等指标。按照年龄性别判断心肺适能等级,并分析VO₂ max与各项指标的相关性。结果本研究中男性占40例(64.5%),VO₂ max、体质量、CAP、ALT、尿酸、体脂率等均显著高于女性(P均＜0.05)。VO₂ max分级为优秀/良好、一般/差和极差的人数,在男性NAFLD组分别为3例、14例和23例,女性分别为10例、11例和1例,两组存在显著性差异(P＜0.001)。在男性患者中,轻中度和重度脂肪肝患者分别为10例和30例,重度脂肪肝患者BMI[(30.0±3.5)比(25.6±3.0)kg/m²]、肝脏CAP值[(357.2±24.1)比(282.3±15.6)dB/m]、腰臀比[(0.98±0.03)比(0.93±0.03)]、体脂率[(29.7±4.3)比(23.9±4.2)%]等更高,而VO₂ max [(30.1±3.2)比(32.8±3.0)mL/(kg·min)]显著低于轻、中度肝脏脂肪变患者(P均＜0.05)。相关性分析表明,男性NAFLD患者VO₂ max与肝脏CAP值、体脂率、内脏脂肪含量、内脏脂肪面积及BMI呈负相关,与四肢骨骼肌指数呈正相关(P均＜0.05)。结论 VO₂ max与肝脏脂肪变的严重程度密切相关。重度脂肪肝患者心肺功能和有氧运动能力低下,尤其男性脂肪肝患者更差。提示男性NAFLD患者运动干预应答不佳,临床治疗时需要根据耐受性制定个体化运动方案。

关键词: 非酒精性脂肪性肝病, 最大摄氧量, 心肺适能, 肝脏脂肪变

Abstract: Objective To investigate the level of cardiopulmonary fitness (CRF) in NAFLD patients and to evaluate the relationship of CRF with liver steatosis, inflammation and liver fibrosis. Methods Sixty-two patients were enrolled in this study. Maximal oxygen uptake (VO₂ max) level was determined to reflect CRF and controlled attenuated parameter (CAP) was tested to reflect liver fat content. Biochemical and body composition indexes were simutaneously detected. The CRF level was graded according to age and gender. The correlation between VO₂ max and various fatty liver associated parameters were analyzed. Results Forty cases (64.5%) of the 62 patients were male, and their VO₂ max, body weight, CAP, ALT, uric acid and body fat rate were significantly higher than those of female patients (all P<0.05). The levels of CRF were classified into 3 grades, i.e., excellent/good, general/poor and very poor. There were 3 cases, 14 cases and 23 cases in male patients, and 10 cases, 11 cases and 1 case in female patients were classified into each of the 3 grades, respectively, with significant difference between the male and female patients (P<0.001). In male patients, there were 10 cases with mild to moderate fatty liver and 30 cases with severe fatty liver. The BMI [(30.0±3.5) vs. (25.6±3.0)kg/m²], CAP value [(357.2±24.1) vs. (282.3±15.6)dB/m], weight hip ratio [(0.98±0.03) vs. (0.93±0.03)]and body fat rate [(29.7±4.3) vs. (23.9±4.2)%] were higher in patients with severe fatty liver, but their VO₂ max [(30.1±3.2) vs. (32.8±3.0)mL/(kg·min)] was significantly lower than that in patients with mild to moderate fatty liver (both P<0.05). By correlation analysis it was shown that VO₂ max was negatively correlated with CAP value, body fat rate, visceral fat content, visceral fat area and BMI in male patients, and positively correlated with appendicular skeletal muscle mass (both P<0.05). Conclusion VO₂ max is closely associated with the severity of liver steatosis. The cardiopulmonary function and aerobic exercise capacity are low in NAFLD patients, especially in male patients. The results indicated that male patients with NAFLD had poor responsiveness to exercise intervention, and individualized exercise programs should be formulated for them according to their tolerance in clinical treatment.

Key words: Nonalcoholic fatty liver disease, Maximal oxygen uptake, Cardiopulmonary fitness, Liver steatosis

刘晓慧, 勾钰淞, 梁珊, 任弘, 李强, 段威, 张晶. 最大摄氧量与男性非酒精性脂肪性肝病患者肝脏脂肪含量相关[J]. 肝脏, 2023, 28(3): 355-359.

LIU Xiao-hui, GOU Yu-song, LIANG Shan, REN Hong, LI Qiang, DUAN Wei, ZHANG Jing. VO₂ max is correlated with liver steatosis in male nonalcoholic fatty liver patients[J]. Chinese Hepatolgy, 2023, 28(3): 355-359.

参考文献

[1] 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版). 实用肝脏病杂志, 2018, 21: 177-186.
[2] Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology, 2018,67:328-357.
[3] Croci I, Coombes JS, Bucher SS, et al. Non-alcoholic fatty liver disease: Prevalence and all-cause mortality according to sedentary behaviour and cardiorespiratory fitness. The HUNT Study. Prog Cardiovasc Dis, 2019a,62:127-134.
[4] Palve KS, Pahkala K, Suomela E, et al. Cardiorespiratory Fitness and Risk of Fatty Liver: The Young Finns Study. Med Sci Sports Exerc, 2017,49:1834-1841.
[5] 董亚南, 覃飞, 瞿超艺, 等. 最大摄氧量评定与应用的研究现状与展望. 中国运动医学杂志, 2017,36:731-739.
[6] Ross R, Blair SN, Arena R, et al. Importance of Assessing Cardiorespiratory Fitness in Clinical Practice: A Case for Fitness as a Clinical Vital Sign: A Scientific Statement From the American Heart Association. Circulation, 2016,134: e653-e699.
[7] 陈敏.大学生身体成分对有氧运动能力影响的研究. 湖南工业职业技术学院学报, 2020,20:93-96.
[8] Kim JA, Choi KM. Sarcopenia and fatty liver disease. Hepatol Int, 2019,13:674-687.
[9] Wijarnpreecha K, Panjawatanan P, Thongprayoon C, et al. Sarcopenia and risk of nonalcoholic fatty liver disease: A meta-analysis. Saudi J Gastroenterol, 2018,24:12-17.
[10] Kantartzis K, Thamer C, Peter A, et al. High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease. Gut, 2009,58:1281-1288.

[1]	苏佩华, 魏梦平, 赵彩彦. 慢性乙型肝炎合并非酒精性脂肪性肝病对肝细胞癌发生及全因死亡影响的meta分析[J]. 肝脏, 2023, 28(3): 299-304.
[2]	王伟, 葛亮, 余宁, 熊晓芸. 非肥胖型非酒精性脂肪性肝病组织学特征及临床结局评价[J]. 肝脏, 2023, 28(3): 360-363.
[3]	陆新元, 丛文铭. 非酒精性脂肪性肝病中肝细胞死亡模式的研究进展[J]. 肝脏, 2023, 28(2): 145-148.
[4]	范芯铷, 晏梓钧, 王庆, 汪慧. 青年消瘦型非酒精性脂肪性肝病相关肝细胞癌2例[J]. 肝脏, 2023, 28(2): 151-154.
[5]	厉绾, 韩艳霞, 谢寿珍, 马颖才, 杨永耿, 李萍英. 减重对CHB和(或)NAFLD患者肝纤维化及脂肪肝程度的影响[J]. 肝脏, 2023, 28(2): 203-206.
[6]	赵建红, 李鸿彬, 程相超, 郭彦伟. 非酒精性脂肪性肝病患者颈动脉内膜中层厚度、颈股动脉脉搏波传导速度分析[J]. 肝脏, 2023, 28(2): 214-217.
[7]	杨诚, 杨华升, 胡建华, 张丽丽, 徐琛. 终末期肝病与营养相关研究的可视化分析[J]. 肝脏, 2023, 28(1): 65-69.
[8]	杨永勤, 冯巩, 李嵘, 孙雪梅, 陈敏, 贺娜. 非酒精性脂肪性肝病与瞬时弹性成像技术研究热点与前沿:基于Web of Sciense数据的实证研究[J]. 肝脏, 2022, 27(9): 1015-1020.
[9]	谢扬, 范建高. 非酒精性脂肪性肝病基础研究及管理对策[J]. 肝脏, 2022, 27(8): 847-848.
[10]	卢嘉惠, 张丛楠, 何鹏园, 欧梦党, 黄明星. 富马酸丙酚替诺福韦治疗慢性乙型肝炎合并脂肪肝的疗效及安全性[J]. 肝脏, 2022, 27(8): 858-862.
[11]	徐梓馨, 廖红雨, 李慧一, 徐铭益. MicroRNA-219在脂毒性环境下对肝细胞脂质代谢、细胞增殖及凋亡的影响[J]. 肝脏, 2022, 27(8): 920-924.
[12]	钱怡婷, 杨文卓. 生活方式干预防治非酒精性脂肪性肝病的现状[J]. 肝脏, 2022, 27(7): 822-825.
[13]	徐旭, 范建高. 非酒精性脂肪性肝病相关肝细胞癌面临的挑战[J]. 肝脏, 2022, 27(6): 620-621.
[14]	王晓伟, 孙静, 王栋. 非酒精性脂肪性肝病对儿童和青少年慢性乙型肝炎抗病毒治疗反应的影响[J]. 肝脏, 2022, 27(5): 557-560.
[15]	宋叶雨, 范建高. 肌肉减少症与非酒精性脂肪性肝病共同的发病机制[J]. 肝脏, 2022, 27(4): 494-496.